HYDERABAD: A Landmark Achievement in Biotechnology

The Indian National Science Academy (INSA) has awarded its esteemed India fellowship for 2025 to Dr. Krishna Ella, the co-founder and executive chairman of Bharat Biotech. This recognition comes in light of Dr. Ella's significant contributions to the advancement of vaccine technologies and his pioneering efforts in biotechnology that led to the development of India's first indigenous Covid-19 vaccine, Covaxin.

Joining the Ranks of Distinguished Fellows

With this fellowship, Dr. Ella joins an elite group of INSA fellows, including notable figures such as ISRO chairman Dr. S Somanath and Infosys co-founder Kris Gopalakrishnan. As a fellow, Dr. Ella will have the privilege to vote at general meetings and nominate individuals for fellowships and awards, further influencing the future of scientific research and innovation in India.

Bharat Biotech's Global Impact

Since its inception in 1996, Bharat Biotech has developed a portfolio of 18 vaccines, delivering over nine billion doses to more than 125 countries. The company's response to the Covid-19 pandemic was remarkable, not only for Covaxin but also for the development of iNCOVACC, a novel intranasal Covid-19 vaccine.

INSA's Role in Promoting Science

Established in 1935, INSA has been pivotal in promoting scientific knowledge and its applications in India. It serves as a coordinating body among various scientific institutions, advocating for the interests of scientists and showcasing India's scientific achievements on the global stage.